TPG Biologics (6521)

As of October 31, 2018, TPG Biologics, Inc. was acquired by Lumosa Therapeutics Co., Ltd. TPG Biologics, Inc., a biotechnology company, researches and develops biologics. The company offers contract research services in the areas of mammalian cell line development and process development. It provides gene construction and transfection, antibody humanization, cell line generation, scalable process development, and protein production and purification services. The company also offers production clones for various biosimilar antibodies, including bevacizumab for the treatment of cancer and eye disease; cetuximab to treat dead, neck, and, colorectal cancer; golimumab and tocilizumab for rheumatoid arthritis; infliximab for the treatment of autoimmune disease; omalizumab for allergic asthma; trastuzumab to treat breast cancer; and ustekinumab for the treatment of psoriasis. In addition, it provides production clone for a biosimilar of thyrotropin alfa. Further, the company develops ECC01, a dual-function fusion protein drug that targets and binds to tumor associated antigens, and converts a non-toxic prodrug into a cytotoxic chemodrug. It has a collaborative research agreement with NanoCarrier Co., Ltd. for the development of antibody/drug-conjugated micelles technology. The company serves companies in Taiwan and internationally. TPG Biologics, Inc. was founded in 2007 and is based in Taipei, Taiwan.